Merck to test experimental sac-TMT antibody-drug conjugate with Keytruda in lung cancer trial
read at Endpoints ↗Neutral
Merck announced it will start a clinical trial testing its experimental antibody-drug conjugate sac-TMT together with the immunotherapy Keytruda in patients with lung cancer.
The study will assess the safety and efficacy of the combination and is intended to broaden Merck’s oncology portfolio as the company prepares for the upcoming patent expiration of Keytruda.
Details on the trial design, enrollment size or timeline were not disclosed, but the announcement signals Merck’s continued investment in next-generation cancer therapies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Merck plans trial of sac-TMT combo with Keytruda in lung cancer”
read at Endpoints ↗92 words · retrieved Aug 4
comments(0)
5-min edit window · permanent after that